ClinicalTrials.Veeva

Menu

Childhood Toxin Perception Survey (PERTOXE)

C

Centre Médico-Chirurgical de Réadaptation des Massues Croix Rouge Française

Status

Enrolling

Conditions

Cerebral Palsy (CP)

Treatments

Other: Patient-Reported Outcome Measures

Study type

Observational

Funder types

Other

Identifiers

NCT07377201
2025-A01186-43 (Other Identifier)
2025_09_PERTOXE_RIPH3

Details and patient eligibility

About

Context:

Most medical and surgical interventions for individuals with Cerebral Palsy (CP)-such as botulinum toxin injections, orthopedic surgery, and rehabilitation-occur during childhood. While these treatments are costly and resource-intensive, there is a significant lack of long-term data regarding their effectiveness in adulthood. Furthermore, the perspective of adult patients on the care they received as children is rarely documented. Understanding this "patient-centered" perspective is vital, as care aligned with an individual's values is proven to result in higher satisfaction and better health outcomes.

Problem Statement While botulinum toxin (BTX) has been the gold standard for treating focal spasticity since 2009, it is an iterative (repeated) treatment that can involve procedure-induced pain. At present, there is limited knowledge about how adults with CP perceive the long-term impact of childhood vaccinations. The emotional and physical burden of repeated treatments during development is also not well understood, as are the coping strategies developed by these individuals to manage the stress and pain associated with long-term medical care.

Objectives

The PERTOXE study is a prospective study designed to explore the transition from childhood care to adult life for individuals with CP. Its primary goals are:

Perception of Care: To evaluate how adults with CP perceive the effectiveness and impact of the botulinum toxin injections they received during childhood.

Lived Experience: To document the subjective experience of treatment, including induced pain and the quality of communication with healthcare providers.

Coping Mechanisms: To explore the "coping strategies" these individuals use to face stressful medical events and chronic functional decline.

Significance As the lifespan of individuals with CP increases, understanding long-term outcomes is a research priority. By collecting data from adults, this study aims to improve current pediatric practices, ensuring that childhood interventions better support a high quality of life, functional maintenance, and psychological well-being in adulthood.

Enrollment

500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants aged 18 years or older
  • Diagnosed with cerebral palsy
  • Received repeated toxin injections during childhood (> 2 series of injections)
  • Agreeing to complete the questionnaire
  • Possessing sufficient cognitive abilities, particularly in terms of reading comprehension and oral comprehension (even if someone had to physically assist them in responding)
  • All levels of the GMFCS classification 1 to 5

Exclusion criteria

  • Individuals who do not meet the above criteria, as confirmed by the statements in Part 1 of the survey, will be automatically excluded from the study.

Trial design

500 participants in 1 patient group

Adults with cerebral pasly previously treated with botulinum toxin
Treatment:
Other: Patient-Reported Outcome Measures

Trial contacts and locations

1

Loading...

Central trial contact

Dr Emmanuelle Chaleat-Valayer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems